Company: INMB
Filing Date: 2025-03-07
Form Type: 424B5
Source: 0001213900-25-021719
Chunk: 14

Company: Inmune Bio, Inc.
Filing Date: 2025-03-07
Form: 424B5
Chunk 14
---
, including sponsoring the supply of CORDStrom to UK patients
enrolled in an open label continuation of the Mission EB study.

Debt Payoff

During December 2024, the Company paid off its
term loan with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P.

NIH Grant

During 2024, the Company was notified that its
NIH grant to treat TRD with XPro was reduced from $2.9 million to $2.0 million.

Amendment to Rights Agreement

On December 30, 2020, the Board of Directors (the
“Board”) of the Company, approved and adopted the Rights Agreement, dated as of December 30, 2020 (the “Rights Agreement”),
by and between the Company and VStock Transfer, LLC, as rights agent. Pursuant to the Rights Agreement, the Board declared a dividend
of one preferred share purchase right (each, a “Right”) for each outstanding share of common stock. The Rights were distributable
to stockholders of record as of the close of business on January 11, 2021. The Rights Agreement was amended on December 20, 2021, December
9, 2022, and on December 13, 2023. On December 6, 2024, the Company further amended its Rights Agreement, extending the expiration of
the Rights Agreement to December 30, 2025.

Corporate Information

Our principal executive offices are located at
225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432. Our telephone number is (858) 964-3720. We maintain an Internet website at
www.inmunebio.com. The information contained on, connected to or that can be accessed via our website is not part of this prospectus supplement.
We have included our website address in this prospectus supplement as an inactive textual reference only and not as an active hyperlink.

<div align='center'>S-5</div>

THE OFFERING

| Common stock being offering by us:                                 |     | 3,898,852 shares of common stock issuable from time to time upon exercise of the Warrants, consisting of (i) April 2024 Warrants to purchase 571,592 shares of common stock, (ii) Second April 2024 Warrants to purchase 986,000 shares of common stock, and (iii) September 2024 Warrants to purchase 2,341,